AU2012321444B2 - Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof - Google Patents

Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof Download PDF

Info

Publication number
AU2012321444B2
AU2012321444B2 AU2012321444A AU2012321444A AU2012321444B2 AU 2012321444 B2 AU2012321444 B2 AU 2012321444B2 AU 2012321444 A AU2012321444 A AU 2012321444A AU 2012321444 A AU2012321444 A AU 2012321444A AU 2012321444 B2 AU2012321444 B2 AU 2012321444B2
Authority
AU
Australia
Prior art keywords
composition
sulfur
tac
sodium
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012321444A
Other languages
English (en)
Other versions
AU2012321444A1 (en
AU2012321444A2 (en
Inventor
Gabriel GOJON ROMANILLOS
Gabriel Gojon Zorrilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfagenix Inc
Original Assignee
Sulfagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfagenix Inc filed Critical Sulfagenix Inc
Publication of AU2012321444A1 publication Critical patent/AU2012321444A1/en
Publication of AU2012321444A2 publication Critical patent/AU2012321444A2/en
Application granted granted Critical
Publication of AU2012321444B2 publication Critical patent/AU2012321444B2/en
Priority to AU2015210403A priority Critical patent/AU2015210403B2/en
Assigned to SULFAGENIX, INC. reassignment SULFAGENIX, INC. Request for Assignment Assignors: Nuevas Alternativas Naturales, S.A.P.I. de C.V.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2012321444A 2011-09-14 2012-09-13 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof Ceased AU2012321444B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015210403A AU2015210403B2 (en) 2011-09-14 2015-08-06 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534585P 2011-09-14 2011-09-14
US61/534,585 2011-09-14
PCT/MX2012/000086 WO2013055199A1 (es) 2011-09-14 2012-09-13 Preparación y composiciones de azufre con valencia cero. altamente biq-disponibles y sus usos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015210403A Division AU2015210403B2 (en) 2011-09-14 2015-08-06 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof

Publications (3)

Publication Number Publication Date
AU2012321444A1 AU2012321444A1 (en) 2014-05-01
AU2012321444A2 AU2012321444A2 (en) 2014-05-15
AU2012321444B2 true AU2012321444B2 (en) 2015-06-11

Family

ID=47830038

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012321444A Ceased AU2012321444B2 (en) 2011-09-14 2012-09-13 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof
AU2012308501A Abandoned AU2012308501A1 (en) 2011-09-14 2012-09-13 Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
AU2015210403A Ceased AU2015210403B2 (en) 2011-09-14 2015-08-06 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2012308501A Abandoned AU2012308501A1 (en) 2011-09-14 2012-09-13 Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
AU2015210403A Ceased AU2015210403B2 (en) 2011-09-14 2015-08-06 Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof

Country Status (11)

Country Link
US (3) US8771755B2 (enExample)
EP (2) EP2755478A4 (enExample)
JP (2) JP2014526511A (enExample)
CN (2) CN104080339B (enExample)
AU (3) AU2012321444B2 (enExample)
BR (3) BR112014005144B1 (enExample)
CA (2) CA2847264A1 (enExample)
ES (1) ES2739628T3 (enExample)
HK (1) HK1200278A1 (enExample)
MX (3) MX360050B (enExample)
WO (2) WO2013040240A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US10920020B2 (en) 2011-08-11 2021-02-16 Arizona Board Of Regents On Behalf Of The University Of Arizona 3D-printing of ultra-high refractive index polymers
WO2017011533A1 (en) 2015-07-13 2017-01-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials
EP2742084A1 (en) 2011-08-11 2014-06-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them
US9567439B1 (en) 2011-08-11 2017-02-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Sulfur composites and polymeric materials from elemental sulfur
US11795248B2 (en) 2011-08-11 2023-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Copolymerization of elemental sulfur and epoxy functional styrenics
US11015023B2 (en) 2011-08-11 2021-05-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Fire retardant compositions utilizing elemental sulfur
US8771755B2 (en) * 2011-09-14 2014-07-08 Nuevas Alternativas Naturales, S.A.P.I. de C.V. Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
JP2017517603A (ja) * 2014-02-14 2017-06-29 ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＴｈｅ Ａｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ 元素状硫黄に由来する硫黄複合材及び重合体材料
US10894863B2 (en) 2014-02-14 2021-01-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Cathode materials for Li—S batteries
US9795676B2 (en) 2014-03-03 2017-10-24 Shayne Kenneth Morris Chromium 4-hydroxyisoleucinate compound methods for prepartion and use
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
JP6806965B2 (ja) * 2014-07-29 2021-01-06 国立大学法人 筑波大学 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法
WO2016159612A1 (ko) 2015-03-27 2016-10-06 서울대학교산학협력단 폴리설파이드 공중합체 나노입자 및 그의 제조 방법
US10238685B2 (en) * 2015-12-02 2019-03-26 Johnson & Johnson Consumer Inc. Compositions containing polymeric sulfur and uses thereof
US20170252369A1 (en) * 2016-03-03 2017-09-07 Frederick J. Sawaya Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases
CN107281215A (zh) * 2016-04-01 2017-10-24 复旦大学附属妇产科医院 硫化氢供体硫氢化钠在制药中的用途
WO2018107169A1 (en) 2016-12-09 2018-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Metallopolymers for catalytic generation of hydrogen
PL3579888T3 (pl) * 2017-02-09 2024-05-27 Noxsano Inc. Kompozycje wytwarzające elektrochemiczny transmiter oraz sposoby ich stosowania oraz opatrunki i układy leczenia, w których się je stosuje
US20180271823A1 (en) * 2017-03-23 2018-09-27 Washington State University Sulfur-based broad spectrum antivirals
US11674005B2 (en) 2017-06-15 2023-06-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization
FR3072024A1 (fr) * 2017-10-11 2019-04-12 Olivier Petitjean Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale
CN108486081B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物巯基丙酮酸硫转移酶及其应用
US12161664B2 (en) 2018-08-28 2024-12-10 The Regents Of The University Of California Tetrathionate for cyanide and methylmercaptan poisoning
US20220401554A1 (en) * 2019-11-07 2022-12-22 Cornell University Use of membrane inhibitors to enhance vaccine development against enveloped viruses
MX2022013814A (es) * 2020-05-04 2022-11-30 Sulfagenix Inc Tratamiento de infecciones virales.
FR3125409A1 (fr) * 2021-07-26 2023-01-27 Nuribiol Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine
IT202100021548A1 (it) * 2021-08-09 2023-02-09 Universita’ Di Pisa Coniugati della metformina e loro impiego terapeutico
WO2023079466A2 (en) * 2021-11-03 2023-05-11 Sulfagenix, Inc. Treatment of sequelae of coronavirus infections
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto
WO2024127426A1 (en) * 2022-12-12 2024-06-20 Polishetty Ravishankar An herbal formulation prs-01 for regeneration of the cardiomyocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213050B (it) * 1986-03-14 1989-12-07 Schiena Ricerche Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare
US5100653A (en) * 1991-02-08 1992-03-31 Giovanni Campo Topical compositions for treating mouth tissues
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6514489B1 (en) 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
AUPS255402A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with oxidative stress
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CN1320925C (zh) * 2005-03-30 2007-06-13 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US20100172992A1 (en) * 2006-06-02 2010-07-08 Natural Ma Inc. Pathogenic attenuation via the administration of an equilibiotic compound
US7923037B2 (en) 2006-10-05 2011-04-12 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
WO2008089439A2 (en) * 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
EP2170356A1 (en) * 2007-06-25 2010-04-07 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
EP2167068A2 (en) 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
CN101467991B (zh) * 2007-08-02 2012-02-01 复旦大学 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途
EP2326321A1 (en) 2008-09-12 2011-06-01 Inserm (Institut National de la Santé et de la Recherche Scientifique) Taurine or taurine-like substances for the prevention of brain oedema
RU2406477C1 (ru) 2009-08-25 2010-12-20 Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов
US8680151B2 (en) * 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
US9096504B2 (en) * 2010-12-01 2015-08-04 Washington State University Controlled chemical release of hydrogen sulfide
US8771755B2 (en) * 2011-09-14 2014-07-08 Nuevas Alternativas Naturales, S.A.P.I. de C.V. Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Also Published As

Publication number Publication date
BR112014004859A2 (pt) 2017-06-13
US8771755B2 (en) 2014-07-08
US20130064904A1 (en) 2013-03-14
AU2012308501A1 (en) 2014-03-13
CN104080339A (zh) 2014-10-01
CA2847264A1 (en) 2013-03-21
MX2014003288A (es) 2017-03-09
EP2756757A1 (en) 2014-07-23
JP2014532042A (ja) 2014-12-04
WO2013040240A1 (en) 2013-03-21
CA2847589A1 (en) 2013-04-18
CA2847589C (en) 2019-11-26
HK1200277A1 (en) 2015-08-07
EP2756757A4 (en) 2015-05-20
CN104080334A (zh) 2014-10-01
EP2755478A4 (en) 2015-06-10
BR112014005144B1 (pt) 2021-06-08
WO2013055199A1 (es) 2013-04-18
AU2012321444A1 (en) 2014-05-01
AU2015210403B2 (en) 2016-11-24
JP5992525B2 (ja) 2016-09-14
MX2014003289A (es) 2016-05-16
US20150064286A1 (en) 2015-03-05
US20140322361A1 (en) 2014-10-30
CN104080339B (zh) 2016-09-28
HK1200278A1 (en) 2015-08-07
MX360050B (es) 2018-10-19
AU2012321444A2 (en) 2014-05-15
BR112014005144A2 (pt) 2017-04-18
MX386642B (es) 2025-03-19
BR122020020392B1 (pt) 2021-09-08
AU2012308501A2 (en) 2014-04-17
EP2756757B1 (en) 2019-04-24
ES2739628T3 (es) 2020-02-03
EP2755478A1 (en) 2014-07-23
AU2015210403A1 (en) 2015-09-03
JP2014526511A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
AU2012321444B2 (en) Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof
Greenshields et al. Piperine inhibits the growth and motility of triple-negative breast cancer cells
CA2844910C (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
US9623042B2 (en) Combination preparation for improving sperm quality
WO2015181737A1 (en) Pharmaceutical combination for the treatment of cancer
WO2014116097A2 (es) Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox
WO2015187649A1 (en) Methods and compositions for treating nitric oxide deficiency disorders and related conditions
ES2906614T3 (es) Agente para evitar o mejorar el deterioro de la función cerebral
ES2606200T3 (es) Composición farmacéutica para su uso en el tratamiento o prevención de deficiencias vitamínicas y minerales en pacientes que han sido sometidos a una cirugía de baipás gástrico
HK1200277B (en) Preparation and compositions of zero-valent sulphur having high bioavailability, and uses thereof
US20070010492A1 (en) Composition and method for reducing homocysteine caused by drugs containing methyl compounds
Ross Gynecological Cancers
Rangone Anticancer activity of multifunctional Pt (IV) prodrugs
WO2022112806A2 (en) Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof
Javvadi Investigation of the mechanisms involved in radiosensitization of squamous carcinoma cells by the chemopreventive agent curcurmin

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 APR

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
PC Assignment registered

Owner name: SULFAGENIX, INC.

Free format text: FORMER OWNER(S): NUEVAS ALTERNATIVAS NATURALES, S.A.P.I. DE C.V.